PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia and internationally. The company operates through Biopharma, Consumer Health, and Others segments. It offers health care products in the areas of cardiovascular, metabolic, oncology, endocrinology, fertility, and neurodegenerative diseases, as well as general medicines. The company also engages in research an, development, production, and distribution of pharmaceutical and biological prescription medicines to treat colorectal cancer, head and neck cancer, multiple sclerosis, infertility, growth hormone disorders, and diabetes, as well as thyroid disorders, such as hypothyroidism. In addition, it is involved in the office/property leasing and management activities. The company was formerly known as PT Merck Indonesia Tbk and changed its name to PT Merck Tbk in June 2002. The company was founded in 1970 and is based in Jakarta Timur, Indonesia. PT Merck Tbk operates as a subsidiary of Merck Holding GmbH.
Indonesian Market Performance
7D7 Days: 0.6%
3M3 Months: 13.0%
1Y1 Year: 5.8%
YTDYear to Date: 7.7%
The Real Estate sector gained 4.4% while the market remained flat over the last week. As for the longer term, the market has risen 5.8% in the past 12 months. As for the next few years, earnings are expected to grow by 5.8% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.